For decades, treating Alzheimer’s disease in India meant managing symptoms. Medications like rivastigmine and donepezil could slow cognitive decline for a period, but nothing available in the Indian market could actually target the disease process itself — the accumulating amyloid plaques in the brain that are understood to drive the neurodegeneration underlying Alzheimer’s. That changed in May 2026. Lormalzi (Donanemab), developed by Eli Lilly and Company and approved in India by the Central Drugs Standard Control Organisation (CDSCO), became the first anti-amyloid therapy available in the Indian market — and with it, the first medicine in India’s history that directly targets a pathological hallmark of Alzheimer’s disease rather than only managing its symptoms. This is a genuine inflection point for Indian neurology. Here is what it means for patients, families, and hospitals by medicine distributors in Delhi.
